Aptevo Therapeutics is building a robust pipeline of preclinical products, with a focus on cancers with unmet medical need. Several new candidates are being evaluated to expand the pipeline beyond our current oncology targets (ROR1, PSMA, and CD37) expressed in both hematologic indications and solid tumors.

Leveraging our proprietary ADAPTIR™ platform, these new candidates utilize redirected T-cell cytotoxicity (RTCC) to induce tumor cell lysis. Due to the flexibility and ease of building new ADAPTIR candidates, we continue to explore other mechanisms of inducing cytotoxicity, receptor agonism, blockade and cytokine delivery as novel immuno-oncology drugs.